Fig. 8
Proteasome inhibitor bortezomib augments the antitumor efficiency of bevacizumab in vitro and in vivo. a Combined effect of bortezomib and bevacizumab in A549 cells. After incubating cells with increasing concentrations of bortezomib and bevacizumab, cell viability was determined, and the combination index (CI) was calculated by CompuSyn software. b The mouse body weight of the five groups was measured every 3 days after the indicated treatment. c Representative tumors from the five groups are shown (n = 5). d Tumor volume from homografts in different treatment groups was recorded every 3 days. Data are represented as the mean ± S.E.M. (n = 5). e Tumor weight was detected at the time of sacrifice for different treated groups. f Representative images of H&E staining and immuno-histochemical staining of the different treated groups. Scale bar = 50 μm. g Ki67-positive rates in each group. *p < 0.05, **p < 0.01 and ***p < 0.001 compared with the negative control. Data are shown as the mean ± S.E.M. h Western blot analysis of AGR2, PARP, LC3 expression in differentially treated groups. i As liver function tests, ALT and AST were examined at the time of sacrifice for different treated groups. Data are shown as the mean ± S.E.M (n = 5). j, k Locomotor activity of different treated groups was detected at 24 h after each injection. Data are shown as the mean ± S.E.M (n = 15). **p < 0.01 compared with the negative control
